Pharmaceutical, Radiation and Radiopharmaceuticals

The rise of theranostics: Part 5 -- Advice from center administrators

AuntMinnie

JULY 12, 2024

Reshaping the hospital's nuclear medicine and radiopharmaceutical strategy toward theranostics involves intensive and inclusive planning, Beyder explained at SNMMI. Centers for Medicare and Medicaid (CMS) and manufacturers that agree to provide pharmaceuticals at significantly reduced rates for facilities that qualify. The bottom line?

Nuclear Medicine

Nuclear Medicine Radiation Oncology Radiopharmaceuticals Radiation

RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers

Imaging Technology

SEPTEMBER 20, 2023

a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.

Pharmaceutical

Pharmaceutical Radiopharmaceuticals Radiation Diagnostic

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology

Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

Imaging Technology

JULY 25, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals

Radiopharmaceuticals Imaging Pharmaceutical Disease

TerraPower distributes first shipments of Ac-225

AuntMinnie

JANUARY 24, 2024

TerraPower Isotopes has shipped its first samples of Actinium-225 (Ac-225) to two pharmaceutical companies to develop targeted cancer treatments in drug trials. Global demand for Ac-225 is expected to increase as more radiopharmaceutical treatments using Actinium-225 are developed, the company noted.

Pharmaceutical

Pharmaceutical Radiopharmaceuticals Radiation Oncology IT

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

Imaging Technology

AUGUST 29, 2023

Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.

Pharmaceutical

Pharmaceutical Radiopharmaceuticals Clinic Medical

First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

Imaging Technology

JULY 11, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals

Radiopharmaceuticals Imaging Pharmaceutical Disease

NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

Imaging Technology

AUGUST 31, 2023

milla1cf Thu, 08/31/2023 - 15:50 August 31, 2023 — NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. Ac-225 to Curadh for use in its pioneering molecularly targeted radiation (MTR) programs for the treatment of common lethal tumors. “We

Medical

Medical Radiopharmaceuticals Pharmaceutical Radiation

NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

Imaging Technology

JULY 5, 2023

Nucleus will use NorthStar’s Ac-225 for their customers’ radioligand pharmaceutical programs. Ac-225 carries sufficient radiation to cause cell death in a localized area of targeted cells, while its half-life limits unwanted radioactivity in patients. NorthStar is positioned to be the first commercial-scale producer of n.c.a.

Medical

Medical Radiopharmaceuticals Pharmaceutical Radiation

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Imaging Technology

APRIL 3, 2023

Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.

Medical

Medical Radiopharmaceuticals Pharmaceutical Radiation

ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

Imaging Technology

OCTOBER 18, 2023

CNL will provide the starting material for irradiation and initially manage the production process during the interim scale of radiochemical grade 225Ac supply, while ITM will further process the resulting 225Ac to pharmaceutical grade under Good Manufacturing Process (GMP) specifications.

Radiopharmaceuticals

Radiopharmaceuticals Pharmaceutical Radiation Medical

TeleDaaS Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations

Imaging Technology

NOVEMBER 26, 2023

TeleDaaS specializes in delivering clinical-grade, precision-based dosimetry analysis and treatment plans to clinical research organizations (CROs) and pharmaceutical manufacturers. Radiopharmaceuticals are revolutionizing modern cancer treatment and precision dosimetry is a crucial component of this advanced therapy.

Clinic

Clinic Radiopharmaceuticals Radiosensitivity Pharmaceutical

GE HealthCare Closes MIM Software Acquisition

Imaging Technology

APRIL 2, 2024

announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. There is also special focus on radiation therapy and Theranostics. Oncotarget. 2017 Jun 8;8(37):62742-62758.

Healthcare

Healthcare Healthcare Radiation Oncology Magnetic Resonance Imaging

Diagnostic Imaging Brief

The rise of theranostics: Part 5 -- Advice from center administrators

RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers

Trending Sources

The rise of theranostics: Part 3 -- What is a theranostics center?

Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

TerraPower distributes first shipments of Ac-225

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

TeleDaaS Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations

GE HealthCare Closes MIM Software Acquisition

Stay Connected